What Has Been the Growth of the Tenosynovitis Drugs Market So Far?
The tenosynovitis drugs market has seen considerable growth due to a variety of factors.
• The market size for drugs addressing tenosynovitis has seen a robust expansion in recent times. It is predicted to escalate from $1.19 billion in 2024 to $1.29 billion in 2025, with a compound annual growth rate (CAGR) of 8.3%.
Factors contributing to this growth during the historic timeframe include a greater occurrence of sports-related injuries, an aging population, an increase in healthcare spending, heightened awareness of tenosynovitis, and a greater reliance on biologic treatments.
What Are the Future Growth Projections for the Tenosynovitis Drugs Market?
The tenosynovitis drugs market is expected to maintain its strong growth trajectory in upcoming years.
• The potential for strong expansion is expected in the tenosynovitis drugs market size over the next several years, with a projection to reach $1.75 billion by the year 2029, translating to a compound annual growth rate (CAGR) of 8.0%.
Factors contributing to this predicted rise in the forecast period are the escalating use of telehealth services, the broadening scope of global health initiatives, an increasing occurrence of musculoskeletal ailments, heightened demand for tenosynovitis drugs, and a growing prevalence of chronic diseases. During the forecast period, significant trends to watch include developments in surgical methods, the incorporation of robotics in surgical procedures, advancements in minimally invasive techniques, progress in nanotechnology, and drug formulation innovations.
What Are The Core Factors Supporting Growth In The Tenosynovitis Drugs Market?
The expansion of the tenosynovitis drugs market is expected to be fueled by the rising prevalence of musculoskeletal disorders. Such disorders, which include damage to muscles, tendons, ligaments, nerves and joints, hinder movement and trigger pain. Factors such as aging demographics, sedentary behaviours, and increased occupational hazards contribute to their growing occurrence. Medications for tenosynovitis, including anti-inflammatory drugs and corticosteroids, are utilized to mitigate inflammation and soothe pain related to musculoskeletal conditions that affect tendons and their sheathing. According to a 2023 report by the UK's Office for Health Improvement and Disparities, 17.6% of individuals aged 16 or more cited having a long-term musculoskeletal affliction in 2022, such as arthritis or chronic back or joint issues, a rise from 17.0% in 2021. Thus, the uptick in musculoskeletal disorders is promoting the tenosynovitis drugs market's growth. The advancement of therapeutic approaches is being driven by the increase in sporting injuries. These types of injuries, acquired during athletic pursuits or exercise, can range from minor sprains and strains to more critical fractures or dislocations, and can result from overuse, faulty technique, insufficient pre-workout or stretching, or contact with other participants or items. To treat sports injuries, drugs for tenosynovitis are employed to decrease inflammation in the tendons and alleviate pain, facilitating swifter recuperation and enhanced mobility. In accordance with a report by UK-based insurance intermediary company Howden Group Holdings Ltd in November 2023, the gravity of ankle injuries in the English Premier League soared by 170% between October 2022 and January 2023, alongside a 200% rise in calf/shin injuries and a 130% increase in hamstring injuries, subsequent to the FIFA World Cup Qatar 2022. Thus, the escalating rate of sports injuries propels the growth of the tenosynovitis drugs market.
What Are The Major Segments Within The Global Tenosynovitis Drugs Market?
The tenosynovitis drugs market covered in this report is segmented –
1) By Drug Type: Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Corticosteroids, Antibiotics, Other Drug Types
2) By Indication: De Quervain Tenosynovitis, Stenosing Tenosynovitis, Trigger Finger, Other Indications
3) By Route Of Administration: Oral, Injectable, Topical
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Naproxen, Diclofenac, Celecoxib
2) By Corticosteroids: Prednisone, Methylprednisolone, Dexamethasone, Triamcinolone
3) By Antibiotics: Penicillins, Cephalosporins, Fluoroquinolones, Macrolides
4) By Other Drug Types: Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Biologics, Analgesics
Pre-Book The Tenosynovitis Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing The Tenosynovitis Drugs Market?
Principal players in the tenosynovitis drugs market are honing their focus on advancements in drug formulation, striving to boost effectiveness, mitigate side effects, and spur patient compliance. Cutting-edge drug formulations such as delayed-release and controlled-release technologies furnish prolonged therapeutic impacts, cut back on dosage frequency, and lessen gastrointestinal discomfort, thereby bolstering patient comfort and compliance significantly. For instance, in July 2024, FDA approval for its abbreviated new drug application (ANDA) was granted to ANI Pharmaceuticals Inc., a pharmaceutical firm from the U.S, following which it rolled out Naproxen delayed-release tablets, USP. This drug was launched as the generic equivalent of EC-Naprosyn, the reference listed drug (RLD), offering the identical therapeutic benefits at a lower cost. The delayed-release formulation aimed to provide prolonged pain relief while limiting gastric irritation, marking it as a valuable treatment alternative for inflammatory disorders like arthritis, tendonitis, and tenosynovitis.
Who Are the Key Players In The Tenosynovitis Drugs Market?
Major companies operating in the tenosynovitis drugs market are:
• Pfizer Inc.
• Roche Holding AG
• Bayer AG
• Sanofi S.A.
• AstraZeneca plc
• GSK plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Perrigo Company plc
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Aurobindo Pharma Limited
• Endo International plc
• Lupin Limited
• Mallinckrodt Pharmaceuticals
• Zydus Cadila Healthcare
• AdvaCare Pharma.
What Is The Most Dominant Region In The Tenosynovitis Drugs Market?
North America was the largest region in the tenosynovitis drugs market in 2024. The regions covered in the tenosynovitis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
